Canada approves Covidien generic Cardiolite
Health Canada has approved Covidien's abbreviated new drug submission (ANDS) for its kit for the preparation of Technetium Tc99m Sestamibi injection. Covidien's product is a generic substitute for Cardiolite, a myocardial perfusion imaging agent used for detecting coronary artery disease.

With Health Canada approval of the ANDS, which was filed by Covidien's Canadian subsidiary, the company said the generic product is expected to be available for customers in Canada this summer. The generic product also is available in the United States, the United Kingdom, Denmark, Germany and Puerto Rico.